IMBiologics Corp.

₩13,480As of Sun 8 Nov 2026, 12:00 UTC

KOSDAQ:493280Healthcare

Country South Korea

PE (Fwd) •••

TSR 10Y CAGR —

Div yield —

ROE —

Biotechnology

Beta (5Y) —

PE TTM —

TSR TTM —

Mkt cap ₩199.2B

ROIC —

SE Grade™

Value

Quality

Moat

Consensus

Reference

₩16,947

25.72%

(79.01%)

Hold 11|8|8|12|4

TTM

FYE 31 Dec KRW

FY2016

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026E

Trend

10Y

Peers

6.967

Revenue₩B

19.79

20.78

21.56

22.08

23.26

24.18

25.50

26.20

26.69

27.52

7.325

3.42%

3.64%

18.37

Revenue growth%

9.72

12.07

9.58

7.16

7.68

6.08

6.34

7.77

7.26

7.64

15.92

7.26

7.66

10.09

Gross margin%

15.14

13.77

15.40

13.65

12.56

13.41

12.55

10.99

13.24

14.90

19.91

13.24

13.53

9.24

Operating margin%

17.31

19.74

21.13

20.59

22.82

25.37

23.28

24.75

27.46

26.76

26.46

25.37

23.05

3.20

Net margin%

21.50

24.18

24.41

26.37

26.04

26.59

24.79

25.61

24.48

23.95

28.84

24.79

24.64

32.68

P/E ratio (avg)x

7.549

8.637

8.696

8.289

8.957

8.498

8.600

8.072

9.169

9.632

36.91

8.600

8.618

17.86

EV/EBITx

7.713

8.696

8.977

9.087

10.56

9.939

9.953

9.376

10.70

10.40

14.54

9.953

9.658

18.61

FCF yield (avg)%

27.36

26.61

27.31

27.28

28.79

30.30

30.56

30.61

32.90

35.13

26.25

30.61

29.55

10.87

FCF margin%

1.32

0.40

2.18

2.19

3.48

5.43

7.60

5.56

5.58

7.40

13.31

5.58

4.45

0.398

FCF / Net incomex

1.234

1.201

1.317

1.222

1.171

1.087

0.985

1.018

0.981

0.918

0.153

0.985

1.129

7.79

ROIC%

28.57

28.48

28.31

27.22

24.38

21.98

24.13

21.45

19.26

16.84

22.55

21.45

24.25

10.69

Return on equity%

12.67

14.87

17.79

17.93

15.82

18.56

17.50

17.54

16.12

13.93

15.33

17.50

16.81

17.52

Return on assets%

5.69

5.01

2.26

2.06

4.27

5.74

4.51

5.78

3.97

5.19

14.97

5.19

4.76

767.33

EPS₩

825.12

857.32

880.18

977.68

1,053

993.91

1,058

987.81

1,048

1,100

788.58

0.87%

2.53%

—

19.54

EPS growth%

16.81

16.32

18.55

20.46

21.04

20.27

19.71

16.97

14.82

16.58

7.49

16.97

17.76

1,709

Bookvalue per sh₩

908.23

798.30

752.71

755.07

807.85

779.18

847.34

758.13

727.06

631.36

951.61

(4.81%)

(4.99%)

—

1,114

FCF per share₩

1,089

1,098

1,172

1,109

1,084

1,162

1,077

959.87

978.47

985.86

667.08

(1.89%)

(1.98%)

—

1,394

Dividend per sh₩

1,216

1,241

1,139

1,187

1,098

1,001

973.18

928.11

1,011

953.88

1,618

(2.77%)

(3.39%)

—

7.33

Div yield (avg)%

5.32

2.72

0.40

1.61

2.77

1.67

3.63

4.91

6.80

7.91

16.31

4.91

3.20

9.16

Payout ratio%

2.08

1.23

2.82

2.28

1.44

2.46

1.36

0.40

1.62

2.82

21.92

1.62

1.85

14.78

Shares (diluted)M

13.86

15.35

15.44

14.97

14.20

13.30

12.24

13.66

12.31

13.37

14.50

(1.20%)

(1.07%)

18.80

Buyback yield%

23.17

22.85

22.79

20.27

21.97

23.69

21.60

19.35

21.48

22.55

28.32

21.60

22.26

0.534

D/E ratiox

1.484

1.613

1.673

1.441

1.499

1.582

1.723

1.829

1.830

1.925

1.058

1.829

1.643

10.14

Enterprise value₩B

16.11

16.52

16.94

18.51

17.21

15.88

14.94

15.36

14.43

15.34

20.05

(2.28%)

(0.71%)

21.39

LT debt₩B

23.97

26.08

27.23

28.40

29.71

31.60

28.86

27.43

25.14

26.97

10.80

(1.92%)

1.12%

Peers (US$124.0M)

Cap (US$)

Kangstem Biotech Co.…

125.9M

—

curacle co.,ltd.

122.7M

—

Genome & Company

121.3M

—

Tripartite Therapeutic…

123.6M

—

Capital

TTM

10Y

Leveragex

1.419

—

EBIT/Intx

0.679

0.401

0.372

Own earn%

309.61

245.55

221.88

Sh yield%

26.13

25.36

25.30

Owners

Insiders/Inst%

9.64

41.98

Short interest%

3.89

SBC / revenue%

2.45

Record

10Y

Profitable years

10/10

Revenue growth years

10/10

EPS growth years

10/10

Dividend streakyrs

Op margin range%

17–27

$1 testx

—

Incr. ROIC%

IMBiologics Corp., a biotechnology company, engages in developing immunomodulatory antibody therapeutics to treat autoimmune diseases and cancer. The company uses Optimal Antibody Modality Manufacturing Technology (IM-OpDECon) for developing differentiated treatments for autoimmune diseases and immuno-oncology based on immuno-modulatory biologics.

Growth vs revenue

Latest

Trend

10Y CAGR

Rel growth

Revenue

₩27.52B

3.64%

1.00×

Cost of revenue

₩17.36B

3.82%

1.02×

Operating expenses

₩3.552B

3.79%

1.01×